• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定和表征 CDRH2 中一个意想不到的异构化模体,该模体影响抗体活性。

Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity.

机构信息

Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China.

Department of Molecular Science, BeiGene (Beijing) Co. Ltd, Beijing, China.

出版信息

MAbs. 2023 Jan-Dec;15(1):2215364. doi: 10.1080/19420862.2023.2215364.

DOI:10.1080/19420862.2023.2215364
PMID:37229604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10215015/
Abstract

Aspartic acid (Asp) isomerization is a spontaneous non-enzymatic post-translation modification causing a change in the structure of the protein backbone, which is commonly observed in therapeutic antibodies during manufacturing and storage. The Asps in Asp-Gly (DG), Asp-Ser (DS), and Asp-Thr (DT) motifs in the structurally flexible regions, such as complementarity-determining regions (CDRs) in antibodies, are often found to have high rate of isomerization, and they are considered "hot spots" in antibodies. In contrast, the Asp-His (DH) motif is usually considered a silent spot with low isomerization propensity. However, in monoclonal antibody mAb-a, the isomerization rate of an Asp residue, Asp55, in the aspartic acid-histidine-lysine (DHK) motif present in CDRH2 was found to be unexpectedly high. By determining the conformation of DHK motif in the crystal structure of mAb-a, we found that the Cgamma of the Asp side chain carbonyl group and the back bone amide nitrogen of successor His were in proximal contact, which facilitates the formation of succinimide intermediate, and the +2 Lys played an important role in stabilizing such conformation. The contributing roles of the His and Lys residues in DHK motif were also verified using a series of synthetic peptides. This study identified a novel Asp isomerization hot spot, DHK, and the structural-based molecular mechanism was revealed. When 20% Asp55 isomerization in this DHK motif occurred in mAb-a, antigen binding activity reduced to 54%, but the pharmacokinetics in rat was not affected significantly. Although Asp isomerization of DHK motif in CDR does not appear to have a negative impact on PK, DHK motifs in the CDRs of antibody therapeutics should be removed, considering the high propensity of isomerization and impact on antibody activity and stability.

摘要

天冬氨酸(Asp)异构化是一种自发的非酶翻译后修饰,导致蛋白质骨架结构发生变化,这种变化在治疗性抗体的制造和储存过程中很常见。在结构上具有柔性的区域(如抗体的互补决定区(CDR))中的Asp-Gly(DG)、Asp-Ser(DS)和 Asp-Thr(DT)基序中的Asp 通常会发生高异构化率,被认为是抗体中的“热点”。相比之下,Asp-His(DH)基序通常被认为是低异构化倾向的“静默点”。然而,在单克隆抗体 mAb-a 中,发现 CDRH2 中 Asp-His-Lys(DHK)基序中的一个 Asp 残基(Asp55)的异构化速率出乎意料地高。通过确定 mAb-a 晶体结构中 DHK 基序的构象,我们发现 Asp 侧链羰基和后继 His 的骨架酰胺氮处于近端接触,这有利于形成琥珀酰亚胺中间体,而+2 Lys 在稳定这种构象中起着重要作用。使用一系列合成肽也验证了 DHK 基序中 His 和 Lys 残基的贡献作用。本研究确定了一个新的 Asp 异构化热点 DHK,并揭示了基于结构的分子机制。当 mAb-a 中 20%的 Asp55 发生异构化时,抗原结合活性降低至 54%,但在大鼠中的药代动力学没有受到显著影响。尽管 DHK 基序在 CDR 中的 Asp 异构化似乎对 PK 没有负面影响,但考虑到异构化的高倾向以及对抗体活性和稳定性的影响,抗体治疗药物的 CDR 中的 DHK 基序应该被去除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/1961ce86cc53/KMAB_A_2215364_F0010_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9adfeb7e02a2/KMAB_A_2215364_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/2069a4d11b38/KMAB_A_2215364_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9d05536b4f02/KMAB_A_2215364_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/a365d408698a/KMAB_A_2215364_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/a7c3f4127074/KMAB_A_2215364_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/0396b1ef4459/KMAB_A_2215364_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9a1c143597aa/KMAB_A_2215364_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/b50cfac69776/KMAB_A_2215364_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/f29bb557b591/KMAB_A_2215364_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/1961ce86cc53/KMAB_A_2215364_F0010_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9adfeb7e02a2/KMAB_A_2215364_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/2069a4d11b38/KMAB_A_2215364_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9d05536b4f02/KMAB_A_2215364_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/a365d408698a/KMAB_A_2215364_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/a7c3f4127074/KMAB_A_2215364_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/0396b1ef4459/KMAB_A_2215364_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/9a1c143597aa/KMAB_A_2215364_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/b50cfac69776/KMAB_A_2215364_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/f29bb557b591/KMAB_A_2215364_F0009_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033e/10215015/1961ce86cc53/KMAB_A_2215364_F0010_OC.jpg

相似文献

1
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity.鉴定和表征 CDRH2 中一个意想不到的异构化模体,该模体影响抗体活性。
MAbs. 2023 Jan-Dec;15(1):2215364. doi: 10.1080/19420862.2023.2215364.
2
Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies.两种密切相关单克隆抗体互补决定区中的天冬氨酸异构化
Biochemistry. 2007 Feb 13;46(6):1534-44. doi: 10.1021/bi061500t. Epub 2007 Jan 17.
3
Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.通过聚焦肽图分析监测单克隆抗体天冬氨酸异构化定量方法的验证
PDA J Pharm Sci Technol. 2016;70(6):490-507. doi: 10.5731/pdajpst.2015.006239. Epub 2016 Apr 18.
4
Understanding the pathway and kinetics of aspartic acid isomerization in peptide mapping methods for monoclonal antibodies.理解在单克隆抗体肽图分析方法中天门冬氨酸的异构化途径和动力学。
Anal Bioanal Chem. 2021 Mar;413(8):2113-2123. doi: 10.1007/s00216-021-03176-z. Epub 2021 Feb 5.
5
N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.单克隆抗体互补决定区中天冬氨酸异构化热点的N + 1工程改造
J Pharm Sci. 2016 Feb;105(2):512-518. doi: 10.1016/S0022-3549(15)00185-9.
6
Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.鉴定单克隆抗体中两个不同位置天冬氨酸残基的异构化产物。
Pharm Res. 2012 Jan;29(1):187-97. doi: 10.1007/s11095-011-0534-2. Epub 2011 Aug 2.
7
Structure-Function Assessment and High-Throughput Quantification of Site-Specific Aspartate Isomerization in Monoclonal Antibody Using a Novel Analytical Tool Kit.使用新型分析工具包评估结构-功能并高通量定量单克隆抗体中特异性天冬氨酸异构化。
J Pharm Sci. 2020 Jan;109(1):422-428. doi: 10.1016/j.xphs.2019.08.018. Epub 2019 Aug 27.
8
Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein.鉴定治疗性蛋白中 Asp-Asp 基序中天冬氨酸的消旋化和异构化。
Anal Biochem. 2011 Mar 15;410(2):234-43. doi: 10.1016/j.ab.2010.11.040. Epub 2010 Dec 2.
9
Isomerization and Oxidation in the Complementarity-Determining Regions of a Monoclonal Antibody: A Study of the Modification-Structure-Function Correlations by Hydrogen-Deuterium Exchange Mass Spectrometry.互补决定区中单克隆抗体的异构化和氧化:通过氢氘交换质谱研究修饰-结构-功能关系。
Anal Chem. 2016 Feb 16;88(4):2041-50. doi: 10.1021/acs.analchem.5b02800. Epub 2016 Jan 29.
10
The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.共溶质对单克隆抗体中天冬氨酸残基异构化及构象稳定性的影响
J Pharm Sci. 2007 Jul;96(7):1708-18. doi: 10.1002/jps.20823.

引用本文的文献

1
Determination of Trends Underlying Aspartic Acid Isomerization in Intact Proteins Reveals Unusually Rapid Isomerization of Tau.完整蛋白质中天冬氨酸异构化潜在趋势的测定揭示了Tau蛋白异常快速的异构化。
ACS Chem Neurosci. 2025 Feb 19;16(4):673-686. doi: 10.1021/acschemneuro.4c00721. Epub 2025 Jan 29.
2
Unusually Rapid Isomerization of Aspartic Acid in Tau.微管相关蛋白Tau中天冬氨酸异常快速的异构化
bioRxiv. 2024 Dec 5:2024.12.04.626870. doi: 10.1101/2024.12.04.626870.
3
The Accurate Prediction of Antibody Deamidations by Combining High-Throughput Automated Peptide Mapping and Protein Language Model-Based Deep Learning.

本文引用的文献

1
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue.解析治疗性蛋白质中的脱酰胺和异构化:邻近残基的影响。
MAbs. 2022 Jan-Dec;14(1):2143006. doi: 10.1080/19420862.2022.2143006.
2
Effect of Trastuzumab-HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab.曲妥珠单抗 - HER2复合物形成对曲妥珠单抗互补决定区应激诱导修饰的影响
Front Chem. 2022 Jan 3;9:794247. doi: 10.3389/fchem.2021.794247. eCollection 2021.
3
Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
结合高通量自动肽图分析和基于蛋白质语言模型的深度学习准确预测抗体脱酰胺化
Antibodies (Basel). 2024 Sep 10;13(3):74. doi: 10.3390/antib13030074.
4
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment.通过基于表面等离子体共振的相对结合活性评估,在开发性研究中早期确定治疗性抗体的潜在关键质量属性。
MAbs. 2024 Jan-Dec;16(1):2374607. doi: 10.1080/19420862.2024.2374607. Epub 2024 Jul 2.
5
Stability of Protein Pharmaceuticals: Recent Advances.蛋白质类药物的稳定性:最新进展
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
131 种临床阶段抗体的脱酰胺和差向异构化分析。
MAbs. 2019 Jan;11(1):45-57. doi: 10.1080/19420862.2018.1548233. Epub 2018 Dec 10.
4
Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS.使用IP-LC-MS对动物血清中单抗的体内位点特异性天冬氨酸异构化和天冬酰胺脱酰胺作用进行定量分析。
Bioanalysis. 2016 Aug;8(15):1611-1622. doi: 10.4155/bio-2016-0035. Epub 2016 Jul 11.
5
Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions.基于结构预测抗体可变区中天冬酰胺和天冬氨酸的降解位点
PLoS One. 2014 Jun 24;9(6):e100736. doi: 10.1371/journal.pone.0100736. eCollection 2014.
6
Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.治疗性IgG1分子上观察到的琥珀酰亚胺中间体的体外和体内稳定性比较。
MAbs. 2013 May-Jun;5(3):432-44. doi: 10.4161/mabs.24458. Epub 2013 Apr 22.
7
Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.鉴定单克隆抗体中两个不同位置天冬氨酸残基的异构化产物。
Pharm Res. 2012 Jan;29(1):187-97. doi: 10.1007/s11095-011-0534-2. Epub 2011 Aug 2.
8
Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis.采用高保真胰蛋白酶消化肽图分析准确测定琥珀酰亚胺降解产物。
Anal Chem. 2011 Aug 1;83(15):5912-9. doi: 10.1021/ac200750u. Epub 2011 Jul 1.
9
Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein.鉴定治疗性蛋白中 Asp-Asp 基序中天冬氨酸的消旋化和异构化。
Anal Biochem. 2011 Mar 15;410(2):234-43. doi: 10.1016/j.ab.2010.11.040. Epub 2010 Dec 2.
10
Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies.IgG 1铰链区天冬氨酸异构化的检测与定量:在应激稳定性研究中的快速降解
Anal Chem. 2009 Sep 1;81(17):7454-9. doi: 10.1021/ac901258g.